Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Biotek-snakken
  4. Biotek-snakken — December 2020

Biotek-snakken — December 2020

Planlagt Fastgjort Låst Flyttet Biotek-snakken
456 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • B Offline
    B Offline
    BioShare
    wrote on sidst redigeret af
    #385

    Myovant - super aftale - https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-and-pfizer-announce-collaboration-develop-and - Stiger +23% i pre market 🙂

    1 Reply Last reply
    0
    • B Offline
      B Offline
      BioShare
      wrote on sidst redigeret af
      #386

      Så stopper du lahn1 😉

      1 Reply Last reply
      0
      • L Offline
        L Offline
        lahn1
        wrote on sidst redigeret af
        #387

        🙂

        1 Reply Last reply
        0
        • L Offline
          L Offline
          lahn1
          wrote on sidst redigeret af
          #388

          du er vel med ?

          1 Reply Last reply
          0
          • B Offline
            B Offline
            BioShare
            wrote on sidst redigeret af
            #389

            Conf call. 14:30 i dag.....ja da, købte luk forleden - du pressede mig jo helt vildt 🙂

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #390

              Flot aftale

              1 Reply Last reply
              0
              • B Offline
                B Offline
                BioShare
                wrote on sidst redigeret af
                #391

                Gad vide hvad Sumitomo siger til det!?

                1 Reply Last reply
                0
                • L Offline
                  L Offline
                  lahn1
                  wrote on sidst redigeret af
                  #392

                  Ha ha 😄 kunne ikke finde på at presse nogen 😉

                  1 Reply Last reply
                  0
                  • B Offline
                    B Offline
                    bb
                    wrote on sidst redigeret af
                    #393

                    Super med MYOV - godt man ikke solgte ved PC godkendelsen forleden 🙂 de får 650m upfront - det er 1/3 af selskabets MCAP...

                    1 Reply Last reply
                    0
                    • L Offline
                      L Offline
                      lahn1
                      wrote on sidst redigeret af
                      #394

                      jepp godt man ike solgte på nyheden.

                      1 Reply Last reply
                      0
                      • L Offline
                        L Offline
                        lahn1
                        wrote on sidst redigeret af
                        #395

                        Sumi må have godkendt denne aftale, vel ? er BO aflyst eller er der nu blot to til at byde op ?

                        1 Reply Last reply
                        0
                        • B Offline
                          B Offline
                          bb
                          wrote on sidst redigeret af
                          #396

                          Godt spørgmål vedr. BO på MYOV. Jeg tror ikke på BO, når PFE har indgået en aftale vedr PC og UF som forhåbentligt bliver godkendt 1. juni 2021. Da Sumi ejer over 50 % af aktierne i MYOV, så tænker jeg, at de har godkendt denne deal.

                          1 Reply Last reply
                          0
                          • B Offline
                            B Offline
                            BioShare
                            wrote on sidst redigeret af
                            #397

                            Spero - ligger til super stigning igen i pre market +11%. Ingen nyheder....måske antiboitcs alligevel er ved at blive lidt mere interessant 😉

                            1 Reply Last reply
                            0
                            • B Offline
                              B Offline
                              BioShare
                              wrote on sidst redigeret af
                              #398

                              Men kun hvis man kan stave til antibiotics...sorry for dysleksi, når det går stærkt 🙂

                              1 Reply Last reply
                              0
                              • B Offline
                                B Offline
                                BioShare
                                wrote on sidst redigeret af
                                #399

                                Lynn lyder næsten som en computer. Lader til at Sumi så "beholder" Asien. Men jo ret genialt at pushe produkter igennem Pfizers salgskanaler...super synergier og fantastisk motor. CFO melder at det ikke ændrer noget i relation til Sumi 🙂

                                1 Reply Last reply
                                0
                                • F Offline
                                  F Offline
                                  Fandel
                                  wrote on sidst redigeret af
                                  #400

                                  God morgen...

                                  1 Reply Last reply
                                  0
                                  • SvingtraderenS Offline
                                    SvingtraderenS Offline
                                    Svingtraderen
                                    wrote on sidst redigeret af
                                    #401

                                    It is no surprise that the market trades the stock down on today’s news, currently in the range – 5-10%. Delays and uncertainties do seldom appeal to investors. Based on what we know today, our stance is that this news is about FDA needs sufficient time to review the NDA and that a decision will come on June 17 at the latest.

                                    1 Reply Last reply
                                    0
                                    • SvingtraderenS Offline
                                      SvingtraderenS Offline
                                      Svingtraderen
                                      wrote on sidst redigeret af
                                      #402

                                      When delays occur, it is relevant to emphasize exclusivity protection. Arimoclomol in NPC has Orphan Drug Designation. From approval, it entitles to seven years of market exclusivity in the US and ten years of market exclusivity in the EU. Orphazyme also has a method of use patent for arimoclomol in NPC that expires in 2029, with a potential extension to 2032 (US) and 2034 (EU).

                                      1 Reply Last reply
                                      0
                                      • SvingtraderenS Offline
                                        SvingtraderenS Offline
                                        Svingtraderen
                                        wrote on sidst redigeret af
                                        #403

                                        Impact on Valuation
                                        Orphazyme is a relatively small biopharma company, with not unlimited resources and we also see a risk that the US delay impacts the timeline for the EMA process. Hence, we don’t factor in any sales in the next year in Europe (a minor adjustment). For the US market, we factor in slightly lower sales for the coming years. The estimate changes fall under our margin of safety in our valuation, and we reiterate our Base Case of DKK 145 per share.

                                        1 Reply Last reply
                                        0
                                        • SvingtraderenS Offline
                                          SvingtraderenS Offline
                                          Svingtraderen
                                          wrote on sidst redigeret af
                                          #404

                                          It is important to stress that the NDA remains under priority reviewAlso, we want to highlight the urgent medical need in NPCThe FDA does not plan to hold an advisory committee with expert panelists
                                          Naturally, other factors speak against an earlier approval. It attributes not least to the ongoing pandemic that complicates, for instance, site visits. Further, we cannot rule out that additional factors come up during the extensive NDA review, which could impact the timeline.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper